Neuland Laboratories Reports Q2FY26 Revenue of Rs.516 Crore, 63% YoY
Filing Summary
Neuland Laboratories Limited announced its financial results for the quarter and half year ending September 30, 2025. The company reported a total income of Rs.516 crore for Q2FY26, marking a 63.70% increase from the previous year. The company’s EBITDA reached Rs.156 crore, reflecting a 138.80% year-on-year growth. Profit Before Tax was Rs.129 crore, a 166.00% rise from Q2FY25. The company will hold an earnings call on November 7, 2025, to discuss these results. Neuland Laboratories continues to focus on manufacturing active pharmaceutical ingredients and custom manufacturing solutions.
Neuland Laboratories Limited has released its financial results for the quarter and half year ending September 30, 2025. The company reported a total income of Rs.516 crore for Q2FY26. This represents a 63.70% increase compared to the same quarter in the previous year. The results were announced in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The company’s EBITDA for Q2FY26 was reported at Rs.156 crore, reflecting a significant growth of 138.80% year-on-year. The EBITDA margin increased by 960 basis points to 30.40%. Profit Before Tax (PBT) for the quarter stood at Rs.129 crore, a 166.00% increase from Q2FY25. The PBT margin improved by 960 basis points to 25.00%. The company also reported a Profit After Tax (PAT) of Rs.96 crore, marking a 201.60% increase from the previous year.
Neuland Laboratories specializes in the manufacturing of active pharmaceutical ingredients (APIs), complex intermediates, and custom manufacturing solutions. The company serves customers in approximately 80 countries. The financial performance for the quarter was driven by CMS commercial projects, which contributed to the operating leverage and improved EBITDA margins.
The company will conduct an earnings call on November 7, 2025, at 17:30 hrs. IST. During this call, the management will discuss the company’s performance and respond to questions from participants. The transcript of the conference call will be made available on the company’s website following the event.
Neuland Laboratories has been in operation for over four decades, focusing on the development and manufacturing of APIs. The company has developed more than 300 processes and 100 APIs, with around 995 regulatory filings across various geographies, including the US, EU, and other regions. The company holds certifications from several international health authorities, including the U.S. FDA, TGA (Australia), and EMA (EU).
Neuland Laboratories Limited continues to prioritize its role in the pharmaceutical sector by enhancing its manufacturing capabilities and expanding its customer base. The company remains committed to maintaining its reputation for quality and reliability in the production of pharmaceutical ingredients.